A global survey of physicians' perceptions on cholesterol management: the From The Heart study

被引:36
作者
Erhardt, L. R.
Hobbs, F. D. R. [1 ]
机构
[1] Univ Birmingham, Birmingham B15 2TT, W Midlands, England
[2] Lund Univ, Malmo Univ Hosp, Dept Cardiol, Malmo, Sweden
关键词
D O I
10.1111/j.1742-1241.2007.01420.x
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Aims: Guidelines for cardiovascular disease (CVD) prevention cite high levels of low-density lipoprotein cholesterol (LDL-C) as a major risk factor and recommend LDL-C goals for various risk groups. Lifestyle changes are advised as first-line treatment for patients with high cholesterol, and statins are recommended in high-risk patients. The From The Heart study investigated current practice for the diagnosis and treatment of high cholesterol, and attitudes towards management of the condition. Methods: Physicians were randomly selected from 10 countries, and completed a confidential, semi-structured questionnaire. Results: Of 2790 physicians agreeing to participate, 750 (27%) responded. Physicians rated CVD as the leading cause of death, although physicians (80%) perceived that cancer was the most feared illness among patients. Physicians (71%) believed smoking to be the greatest CVD risk factor, while only 50% thought high cholesterol was the greatest risk. Most physicians (81%) used guidelines to set cholesterol goals, primarily their national guidelines (34%) or the National Cholesterol Education Program Adult Treatment Panel III guidelines (24%). Although only 47% of patients reached and maintained their cholesterol goals, 61% of physicians believed that a sufficient number of patients achieved goals, and 53% did not feel frustrated that they could not always effectively treat patients with CVD. Conclusion: Results indicate discrepancies between guideline recommendations and clinical practice. Although physicians appreciate the risk of CVD, the importance of achieving healthy cholesterol levels for CVD prevention does not seem to be widely endorsed. There is a need for improved communication regarding the importance of cholesterol lowering and investigation of initiatives to improve goal achievement among physicians.
引用
收藏
页码:1078 / 1085
页数:8
相关论文
共 32 条
[1]
Amarenco P, 2006, NEW ENGL J MED, V355, P549
[2]
[Anonymous], 2002, World Health Report, 2002: Reducing risks, promoting healthy life
[3]
Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention - The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study [J].
Athyros, VG ;
Papageorgiou, AA ;
Mercouris, BR ;
Athyrou, VV ;
Symeonidis, AN ;
Basayannis, EO ;
Demitriadis, DS ;
Kontopoulos, AG .
CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (04) :220-228
[4]
Bourgault C, 2005, CAN J CARDIOL, V21, P1187
[5]
BRADY AJB, 2005, BR J CARDIOL, V12, P397
[6]
Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[7]
Quality of cardiovascular disease preventive care and physician/practice characteristics [J].
Christian, AH ;
Mills, T ;
Simpson, SL ;
Mosca, L .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2006, 21 (03) :231-237
[8]
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[9]
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[10]
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3